IS4814A - Tilbúin HIV gen - Google Patents

Tilbúin HIV gen

Info

Publication number
IS4814A
IS4814A IS4814A IS4814A IS4814A IS 4814 A IS4814 A IS 4814A IS 4814 A IS4814 A IS 4814A IS 4814 A IS4814 A IS 4814A IS 4814 A IS4814 A IS 4814A
Authority
IS
Iceland
Prior art keywords
hiv gene
prepared
prepared hiv
gene
hiv
Prior art date
Application number
IS4814A
Other languages
English (en)
Inventor
W. Shiver John
Davies Mary-Ellen
C. Freed Daniel
A. Liu Margaret
C. Perry Helen
Original Assignee
Merck & Co., Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607293.9A external-priority patent/GB9607293D0/en
Application filed by Merck & Co., Inc filed Critical Merck & Co., Inc
Publication of IS4814A publication Critical patent/IS4814A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IS4814A 1996-02-22 1998-07-30 Tilbúin HIV gen IS4814A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1208296P 1996-02-22 1996-02-22
GBGB9607293.9A GB9607293D0 (en) 1996-04-09 1996-04-09 Synthetic hiv env genes
PCT/US1997/002294 WO1997031115A2 (en) 1996-02-22 1997-02-18 Synthetic hiv genes

Publications (1)

Publication Number Publication Date
IS4814A true IS4814A (is) 1998-07-30

Family

ID=26309076

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4814A IS4814A (is) 1996-02-22 1998-07-30 Tilbúin HIV gen

Country Status (27)

Country Link
EP (1) EP0904380B1 (is)
JP (1) JP2000505299A (is)
KR (1) KR19990087126A (is)
CN (1) CN1216064A (is)
AR (1) AR005930A1 (is)
AT (1) ATE309366T1 (is)
AU (1) AU729231B2 (is)
BG (1) BG102784A (is)
BR (1) BR9707672A (is)
CO (1) CO4600706A1 (is)
CZ (1) CZ266798A3 (is)
DE (1) DE69734585T2 (is)
EE (1) EE9800257A (is)
ES (1) ES2251734T3 (is)
HR (1) HRP970092A2 (is)
HU (1) HUP9901112A3 (is)
ID (1) ID16021A (is)
IL (1) IL125547A0 (is)
IS (1) IS4814A (is)
NO (1) NO983876L (is)
NZ (1) NZ331161A (is)
PE (1) PE43298A1 (is)
PL (1) PL328730A1 (is)
SK (1) SK112998A3 (is)
TR (1) TR199801615T2 (is)
WO (1) WO1997031115A2 (is)
YU (1) YU35498A (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
WO1997048370A2 (en) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
DK0969862T3 (da) * 1997-02-07 2007-02-12 Merck & Co Inc Syntetisk HIV gag-gener
US7105724B2 (en) 1997-04-04 2006-09-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
EP1012257A4 (en) 1997-04-04 2004-08-18 Donald P Weeks METHODS AND MATERIALS FOR PRODUCING AND USING TRANSGENIC ORGANISMS DEGRADING DICAMBA
CN1325646C (zh) * 1997-10-20 2007-07-11 Gtc生物治疗学公司 修饰的核酸序列以及增加细胞系统中mRNA水平和蛋白质表达的方法
AU2003200914B2 (en) * 1997-10-20 2007-02-01 Gtc Biotherapeutics, Inc. Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
EP1433851A3 (en) * 1998-12-31 2004-10-13 Chiron Corporation Improved expression of HIV polypeptides and production of virus-like particles
EP1535995A1 (en) * 1998-12-31 2005-06-01 Chiron Corporation Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
US6602705B1 (en) * 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6395714B1 (en) * 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc HIV VACCINE COMPRISING A GAG GENE VEHICLE ADENOVIRUS
EP2278021A3 (en) 1999-11-01 2011-05-18 Novartis Vaccines and Diagnostics, Inc. Expression vectors, transfection systems, and method of use thereof
JP2003520786A (ja) * 1999-12-22 2003-07-08 メルク エンド カムパニー インコーポレーテッド コドン最適化ｈｉｖ−１ｐｏｌおよび修飾ｈｉｖ−１ｐｏｌを発現するポリヌクレオチドワクチン
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
CA2425152A1 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
CA2634992C (en) 2001-07-05 2012-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
BR0212619A (pt) * 2001-09-20 2004-08-17 Glaxo Group Ltd Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo
CA2551560A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
US7855326B2 (en) 2006-06-06 2010-12-21 Monsanto Technology Llc Methods for weed control using plants having dicamba-degrading enzymatic activity
UA102507C2 (ru) 2006-10-16 2013-07-25 Монсанто Текнолоджи Ллс Способ улучшения здоровья растений
US7838729B2 (en) 2007-02-26 2010-11-23 Monsanto Technology Llc Chloroplast transit peptides for efficient targeting of DMO and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ262582A (en) * 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
EP1170368B1 (en) * 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
US6630455B1 (en) * 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン

Also Published As

Publication number Publication date
EP0904380B1 (en) 2005-11-09
ATE309366T1 (de) 2005-11-15
DE69734585D1 (de) 2005-12-15
WO1997031115A3 (en) 1997-10-09
HUP9901112A2 (hu) 1999-07-28
AR005930A1 (es) 1999-07-21
SK112998A3 (en) 2000-04-10
DE69734585T2 (de) 2006-08-10
HUP9901112A3 (en) 2001-06-28
BG102784A (en) 1999-05-31
EE9800257A (et) 1999-02-15
AU729231B2 (en) 2001-01-25
PL328730A1 (en) 1999-02-15
NO983876L (no) 1998-10-21
WO1997031115A2 (en) 1997-08-28
CZ266798A3 (cs) 1999-03-17
HRP970092A2 (en) 1998-04-30
EP0904380A2 (en) 1999-03-31
CN1216064A (zh) 1999-05-05
ES2251734T3 (es) 2006-05-01
NO983876D0 (no) 1998-08-21
IL125547A0 (en) 1999-03-12
JP2000505299A (ja) 2000-05-09
KR19990087126A (ko) 1999-12-15
TR199801615T2 (xx) 1998-11-23
NZ331161A (en) 2000-03-27
CO4600706A1 (es) 1998-05-08
ID16021A (id) 1997-08-28
AU2124697A (en) 1997-09-10
PE43298A1 (es) 1998-08-29
BR9707672A (pt) 1999-04-13
YU35498A (sh) 1999-07-28

Similar Documents

Publication Publication Date Title
IS4814A (is) Tilbúin HIV gen
DE69840172D1 (de) Rna exportelement
ATA93198A (de) Fluoxetinpellets
NO996435L (no) Polymerisasjonsprosess
ID21013A (id) Deret nukleotida antipeka
DE69825615D1 (de) Gaseinführung
NO20003168L (no) Polymerisasjonsmetode
DE69816586D1 (de) Beta-Carotenhydroxylase Gen
DE59810608D1 (de) Stapelvorrichtung
DE59809614D1 (de) Backofen
ID24444A (id) GEN dtsR PEKA-TEMPERATUR
ATA111897A (de) Kimme
DE59809195D1 (de) Gebläsebrenner
NO993432D0 (no) Polymerisasjonsprosess
ATE236897T1 (de) 3-benzylpiperidine
ATA112597A (de) Snowboard - bindung
DE59811530D1 (de) Zange
PT1015447E (pt) Derivado piperidinilmetiloxazolidinona
DE69835157D1 (de) Reihenelektroden-anodisierung
DE69810075D1 (de) Kran
FR2770103B1 (fr) Bigoudi perfectionne
ATA86797A (de) Verschleissschuh
FI972633A (fi) Tulisija
NO996436D0 (no) Polymerisasjonskatalysator
FI974129A (fi) Apuväline